Previous Article | Next Article 
Journal of Virology, November 1998, p. 9150-9156, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Epstein-Barr Virus Contributes to the Malignant
Phenotype and to Apoptosis Resistance in Burkitt's Lymphoma Cell
Line Akata
Jun
Komano,
Makoto
Sugiura, and
Kenzo
Takada*
Department of Virology, Cancer Institute,
Hokkaido University School of Medicine, Sapporo 060-8638, Japan
Received 19 May 1998/Accepted 11 August 1998
 |
ABSTRACT |
In the present study, we established an in vitro system
representing the Burkitt's lymphoma (BL)-type Epstein-Barr virus (EBV) infection which is characterized by expression of EBV-determined nuclear antigen 1 (EBNA-1) and absence of EBNA-2 and latent membrane protein 1 (LMP1) expression. EBV-negative cell clones isolated from the
EBV-positive BL line Akata were infected with an EBV recombinant
carrying a selectable marker, and the following selection culture
easily yielded EBV-infected clones. EBV-reinfected clones showed
BL-type EBV expression and restored the capacity for growth on soft
agar and tumorigenicity in SCID mice that were originally retained in
parental EBV-positive Akata cells and lost in EBV-negative subclones.
Moreover, it was found that EBV-positive cells were more resistant to
apoptosis than were EBV-negative cells. EBV-infected cells expressed
the bcl-2 protein, through which cells might become resistant to apoptosis, at a higher level than did uninfected cells.
This is the first report that BL-type EBV infection confers apoptosis
resistance even in the absence of expression of LMP1 and BHRF1, both of
which are known to have an antiapoptotic function. Surprisingly,
transfection of the EBNA-1 gene into EBV-negative Akata clones could
not restore malignant phenotypes and apoptosis resistance, thus
suggesting that EBNA-1 alone was not sufficient for conferring them.
Our results suggest that the persistence of EBV in BL cells is required
for the cells to be more malignant and apoptosis resistant, which
underlines the oncogenic role of EBV in BL genesis.
 |
INTRODUCTION |
Epstein-Barr virus (EBV) is a
B-lymphotropic human herpesvirus and, like other herpesviruses,
establishes a lifelong presence in the host. The virus infects the vast
majority of the world's adult population and is well known for its
association with a broad spectrum of benign and malignant diseases,
including infectious mononucleosis (5, 6), Burkitt's
lymphoma (BL) (2, 4), nasopharyngeal carcinoma (11,
26), and B-cell lymphoma in immunocompromised individuals
(reviewed in reference 12). In recent years, there
has been increasing evidence of the association of EBV with other human
malignancies such as gastric carcinoma (7, 16); however, the
role of EBV in tumorigenesis remains to be elucidated. It has been
difficult to clarify it because a good tool has not been available
until the isolation of EBV-negative Akata cells (17).
A BL cell line, Akata, derived from a Japanese patient, has chromosomal
translocation t(8;14) and expresses surface immunoglobulin (Ig) of the
G
class (21). It is now commonly used as a virus source,
a targeting host to generate recombinant EBV, and a tool to study viral
replication since cross-linking surface IgG with anti-IgG induces viral
replication synchronously and efficiently (22). What is
unique in Akata is that it retains the type I latency (14)
which expresses EBV-associated nuclear antigen 1 (EBNA-1), EBV-encoded
nuclear RNAs (EBERs), and a transcript from the BamHI A
region (BARF0) even after long-term culture in vitro. By contrast, most
BL cell lines convert to type III latency (14), in which all
the viral latent genes, including six EBNAs and three latent membrane
proteins (LMPs), are expressed.
It was impossible to isolate EBV-negative cells from originally
EBV-positive BL cell lines previously. But Akata is also unique in this
respect. The parental Akata cells were virtually 100% positive for
EBNA; however, some of them became EBV negative after serial passages.
We successfully isolated both EBV-positive and -negative clones from
the parental Akata cells by the limiting dilution method. The growth
characteristics of these clones were subsequently compared. Although
both clones proliferated at nearly the same rate in serum-rich
conditions, EBV-negative clones could not grow in low-serum conditions.
Furthermore, EBV-positive clones could form colonies on soft agar and
tumor masses in nude mice, while EBV-negative clones could not. It was
suggested that the malignant phenotype of Akata is dependent on the
presence of EBV (17).
In this study, we confirmed this hypothesis more directly by
reinfecting EBV-negative Akata clones with EBV. First, we demonstrated that reinfection resulted in type I latency. Second, we verified that
in reinfected cells two aspects of the parental phenotype, malignancy
and apoptosis resistance, were restored. This is the first report that
BL cells with type I latency are resistant to apoptosis. Third, we
further investigated whether EBNA-1 was responsible for these two
characteristics and found that they were not due to EBNA-1 alone.
 |
MATERIALS AND METHODS |
Cell culture.
The Akata cell line of BL origin was
maintained in RPMI 1640 medium (Nikken or Sigma) supplemented with 10%
fetal bovine serum (FBS) (GIBCO BRL), penicillin (40 U/ml), and
streptomycin (50 µg/ml) at 37°C in a 5% CO2 humidified
atmosphere.
Plasmids, transfection, and cell cloning.
The neomycin
resistance gene (neoR) driven by the simian virus 40 promoter was derived from pcdna3 (Invitrogen). pEBO (10) is
a mammalian plasmid vector that carries the simian virus 40 promoter-driven neoR gene, the EBNA-1 gene, and the
oriP sequence of B95-8 origin. Transfection-grade plasmid
DNA was purified by the CsCl-ethidium bromide method or with a
FlexiPrep Kit (Pharmacia). Plasmids were introduced into Akata cells by
the electroporation method. First, 5 × 106 cells were
suspended in serum-free RPMI 1640, washed twice, and resuspended in 400 µl of ice-cold serum-free RPMI 1640 containing 2 to 10 µg of
plasmid DNA in a 2-mm-gap electroporation cuvette (BTX). The
electroporation was performed with the Electro Cell Manipulator 600 (BTX) set at 180 V, 1 mF, and R1. After transfection, cells were
cultured for 2 days and transfectants were selected in the medium
containing 700 µg of G418 (GIBCO BRL) per ml. For cloning cells,
10,000 cells were transferred to a well of a flat-bottomed 96-well
multiwell plate (Falcon) with 200 µl of selection medium. Half of the
medium was changed every 5 days until colonies emerged. Clones were
expanded and maintained in selection medium.
EBV infection.
Preparation of the virus solution was
described previously (8, 18, 25). First, 5 × 106 cells were suspended in 2 ml of diluted EBV solution
(1:2 to 10) for 60 min at room temperature with continuous mild mixing. Then they were washed three times and cultured for 2 days. Selection and cloning procedures are described above.
Western blot analysis.
Total cell lysate from 5 × 104 cells (corresponding to about 10 µg of protein) was
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Proteins were separated in 8, 10, or 15% polyacrylamide gels and
transferred to nitrocellulose membranes (Schleicher & Schuell) by a
semidry system (Nihon Eido). Blots were blocked in 5%
milk-Tris-buffered saline-Tween. For immunostaining, blots were
incubated in a mixture of human sera for EBNAs; S12 monoclonal antibody
for LMP1; a mixture of monoclonal antibodies, bcl-2(Ab-1)/100 and
bcl-2(Ab-1)/112 for bcl-2; and MAB8188 monoclonal antibody for BHRF1
(Chemicon). The ECL method was used for signal detection according to
the manufacturer's protocol (Amersham).
Reverse transcriptase PCR (RT-PCR).
Total RNA was extracted
from Akata cells with Trizol reagent (GIBCO BRL) according to the
manufacturer's instructions. RNA was solubilized in distilled water,
treated with DNase I (GIBCO BRL) at 37°C for 15 min, and then
incubated at 94°C for 10 min to inactivate the enzyme. For each set
of reverse transcription, 2 µg of total RNA was denatured at 94°C
for 10 min in the presence of 10 pmol of 3'-specific primer, chilled on
ice, and incubated at 37°C for 1 h in the presence of 20 mM Tris
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol,
0.5 mM deoxynucleoside triphosphate, 10 U of RNasin (Promega), and 200 U of Moloney murine leukemia virus RT (GIBCO BRL) in a total volume of
20 µl. One hundred nanograms of the cDNA was subjected to
amplification by PCR. The sequence and the genomic coordinates of
oligonucleotides used in the study are listed in Table
1 (1, 3, 19, 23). PCR was
carried out in the presence of 10 mM Tris HCl (pH 8.3)-50 mM KCl-1.5
mM MgCl2-0.4 mM deoxynucleoside triphosphate-10 pmol of
each primer-5 U of Taq polymerase (Takara) in a total
volume of 50 µl. Samples were amplified with a Thermal Cycler 2400 (Perkin-Elmer) for 12 cycles for EBER1 and 35 cycles for the others.
Each amplification consisted of denaturation at 94°C for 30 s,
annealing at 45 to 50°C for 60 s, and extension at 72°C for
60 s. The amplified products were electrophoresed in 2.0% agarose
gels, then vacuum transferred (Pharmacia) to a HyBond N+
nylon membrane (Amersham) under alkaline conditions, and detected by a
3'-end-labeled (Takara) internal probe with the ECL detection system
(Amersham).
Soft agar colony assay.
Ten thousand cells were embedded in
1.5 ml of RPMI 1640 containing 12% FBS and 0.35% Noble agar (Difco)
or 0.5% SeaPlaque agarose (FMC) on a base layer made of RPMI 1640 containing 12% FBS and 0.4% Noble agar or 0.5% SeaPlaque agarose in
a well of a six-well multiwell plate (Falcon). After 2 to 3 weeks of
incubation, all the visible colonies were counted.
Induction of apoptosis.
Cells in the log phase were
incubated for 16 h in the presence of 20 µg of cycloheximide
(Wako) per ml or for 40 h with 1 mM glucocorticoid (Pharmacia and
Upjohn) or exposed to 5 to 10 mJ of UV irradiation in a UV
cross-linker (Bio-Rad) and incubated for 16 h. Viability of cells
was quantified by a colorimetric assay (Cell Titer 96; Promega) that
measured the activity of mitochondrial dehydrogenases. The absorbance
at 570 nm (A570) was measured with a plate
reader (Bio-Rad). Samples from time zero were used as controls. The
survival rate was calculated by the following formula: (% survival
rate) = [(A570 of the sample)
(A570 of the
blank)]/[(A570 of the control)
(A570 of the blank)] × 100.
DNA extraction for low-molecular-weight DNA.
First,
106 cells were lysed in 100 µl of lysis buffer containing
10 mM EDTA, 10 mM Tris HCl (pH 8.0), and 0.5% Triton X-100 and then
kept on ice for 10 min. Supernatants were collected after 20 min by
centrifugation of the sample at 16,000 rpm. Then the supernatant was
treated with proteinase K (100 µg/ml) (Takara) at 55°C for 30 min,
and nucleic acids were precipitated with 2-propanol. Finally, the
pellet was resolved in water containing 2 µg of RNase A. DNA
corresponding to 4 × 105 cells was applied per lane
of agarose gel for electrophoresis.
Statistical analysis.
Statistical significance was assessed
by the Mann-Whitney U test and unpaired Student t test on
paired values. Values of P < 0.05 were considered
significant.
 |
RESULTS |
EBV reinfection of EBV-negative Akata cells results in type I
latency.
We could not isolate EBV-reinfected Akata clones with
either wild-type Akata EBV or B95-8 EBV since the population of
infected cells that could stably retain EBV was extremely low. This was a common phenomenon for EBV infection of all EBV-negative B-cell lines
tested. Instead of the wild-type virus, we used a recombinant Akata
EBV-knockout viral thymidine kinase gene, replaced it with neoR to reinfect EBV-negative clones, and succeeded in
isolating reinfected clones in the selection medium (18).
All the G418-resistant cells were positive for EBNA as shown by an
immunofluorescence assay with human serum (data not shown). Reinfection
was ensured by detecting EBV DNA with cellular DNA extracted from
G418-resistant cells by Southern blotting (data not shown). From more
than a hundred clones, we randomly selected 12 clones which were
subjected to immunoblotting and RT-PCR to identify viral latency.
EBNA-1 was detected by Western blotting, and BARF0, EBER1, and LMP2A were detected by RT-PCR. The clones were negative for EBNA-2, EBNA-3a,
-3b, and -3c (EBNA-3s), and LMP1 by Western blotting and LMP2B by
RT-PCR. They used the Q promoter for EBNA-1 transcription, not the C or
W promoter. In Fig. 1, the results for
three clones are indicated. The pattern of viral gene expression and
the promoter usage of reinfected Akata cells were quite similar to
those of the parental Akata cells. On the other hand, a lymphoblastoid cell line (LCL) immortalized by the same Akata EBV, a representative for type III latency, expressed EBNA-1, -2, and -3s; LMP1 and -2;
EBER1; and BARF0. It utilized the C-W promoter to transcribe EBNAs.
These data were consistent with the conclusion that reinfected Akata
cells possessed type I latency. In addition, the cells retained the
ability to produce virus particles after cross-linking of surface IgG
with anti-IgG.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
EBV gene expression in EBV-reinfected Akata cells. (A)
Reinfected Akata cell clones are positive for EBNA-1 but negative for
EBNA-2, EBNA-3s, and LMP1 by Western blot analysis (arrows at left).
The LCL, which represents type III latency, and parental Akata cells
(EBV positive), which represent type I latency, are used as positive
controls, and EBV-negative cells are used as a negative control.
Molecular masses of protein markers are shown at the right. (B) Three
EBV-reinfected clones are also positive for BARF0 and EBER1 and weakly
positive for LMP2A as demonstrated by RT-PCR. They utilize the Q
promoter for transcription of EBNA-1 mRNA but not the C or W promoter.
Consequently, reinfected clones were proved to have type I latency. LCL
cells are positive for all latent gene expression tested by RT-PCR, and
they utilize C and W promoters to transcribe EBNAs.
|
|
Growth characteristics of reinfected clones.
As reinfected
clones were selected in the presence of G418, we transfected the
neoR gene into the same EBV-negative Akata cell clones and
isolated more than 100 clones. We selected several G418-resistant
clones randomly and compared them with the EBV-reinfected cell clones
in terms of growth characteristics. Both proliferated at nearly the
same rate in RPMI 1640 medium supplemented with 10% FBS. EBV-positive
and -negative clones from the parental Akata cells exhibited distinct
differences in growth in low-serum conditions. However, we could hardly
observe a significant difference between the reinfected cells and the
neoR-transfected cells originating from four independent
EBV-negative Akata cell clones with respect to the growth rate in
medium with 0.1% FBS, in spite of repeated attempts (data not shown).
To examine the malignant phenotype, we first performed a soft agar
colony assay because our previous study revealed that colony
formation
in soft agar is an excellent index for the malignant
phenotype of
Akata. Reinfected cells formed colonies in soft agar,
but
neoR-transfected clones scarcely did (Fig.
2). As shown in
Fig.
2, we tested four
pairs of reinfected and
neoR-transfected
cells, and the
results were the same. This phenotypic difference
was retained for at
least half a year. The absolute numbers of
colonies differed, but this
was presumed to be due simply to the
clonal variation. Furthermore,
each of six EBV-reinfected and
neoR-transfected cell clones
derived from an EBV-negative Akata
cell clone was pooled and assayed
for tumorigenicity in SCID mice.
As shown in Table
2, EBV-reinfected cells produced tumors
at
the sites of inoculation in four of eight mice. Tumor cells
consisted
of EBNA-1-positive cells and were negative for EBNA-2 and
LMP1.
On the other hand,
neoR-transfected cells were not
tumorigenic
in SCID mice.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 2.
Growth in soft agar of neoR-transfected,
EBV-reinfected, and EBNA-1-transfected Akata cell clones. Three sets of
clones originating from four independent EBV-negative Akata clones were
examined in this study (A, B, C, and D). EBV-reinfected cells could
form colonies, but neoR-transfected and EBNA-1-transfected
clones could scarcely do so. It is clear that EBNA-1 is not solely
responsible for the growth of Akata cells in soft agar. Each dot
represents the number of visible colonies of a single clone formed in
soft agar. A total of 104 cells were seeded per well. The
number of clones tested is noted underneath the graph. Values between
the indicated groups (Mann-Whitney U test): *, P < 0.005; **, P < 0.05; ***, P < 0.01.
|
|
Resistance to apoptosis is dependent on the presence of EBV.
The typical morphology and degradation of genomic DNA into nucleosomal
units define apoptosis. Akata cells underwent apoptosis after treatment
of cells with various inducers such as cycloheximide, UV light, and
glucocorticoid. We examined whether there was any difference in the
susceptibility to apoptotic cell death between EBV-infected and
uninfected Akata clones. The percentages of cells that had apoptotic
morphology were 20 to 40% of EBV-positive cells and 50 to 80% of
EBV-negative cells, when cells were treated with cycloheximide for
18 h (Fig. 3A). After treatment with
apoptotic stimuli, EBV-positive Akata cells showed a more prominent DNA laddering than did EBV-negative Akata cells (Fig. 3B). The survival rate was examined by a colorimetric assay that measured the activity of
mitochondrial dehydrogenases. As a result, EBV-positive clones from
parental Akata cells were found to be more resistant to cell death than
were EBV-negative clones (Fig. 4A). In
addition, restoration of the resistance to apoptosis was observed in
the EBV-reinfected Akata clones, as shown in Fig. 4B. This phenotypic
difference was stable for more than 1 year. These findings made it
clear that resistance to apoptosis of Akata cells was dependent on the presence of EBV. It should be noted that EBV-infected Akata cells were
negative for LMP1 and BHRF1, which are known to be antiapoptotic genes.
They were expressed only when virus replication was induced by
incubation of cells with anti-IgG (Fig.
5A and B).

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 3.
Apoptosis in Akata cells. (A) Typical morphology of
apoptotic cells induced by cycloheximide in EBV-negative Akata cells.
Cells were stained with acridine orange (2 µg/ml) and photographed by
laser scanning fluoromicroscopy (Molecular Dynamics). (B) DNA laddering
occurs in response to the treatment with UV radiation (UV),
cycloheximide (CHX), and glucocorticoid (Gluc). DNA from 4 × 105 cells was subjected to 2% agarose gel electrophoresis
and stained with ethidium bromide. Incubation times are given above the
gels. The intensity of the DNA ladder of EBV-negative cells
[Akata( )] is stronger than that from EBV-positive cells
[Akata(+)], suggesting that EBV-negative cells are more liable to die
of apoptosis than are EBV-positive cells.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 4.
EBV-infected cells are resistant to apoptosis.
EBV-negative [EBV( )] and EBV-positive [EBV(+)] clones derived
from the parental Akata cells (A) and neoR-transfected,
EBV-reinfected, and EBNA-1-transfected clones derived from an
EBV-negative Akata clone (B) were exposed to apoptotic stimuli. The
average relative survival rates (percent) and error bars (standard
errors of the means) are shown. (A) The average relative survival rate
of the EBV-positive clones is significantly higher than that of the
EBV-negative clones (*, < 0.001), suggesting that EBV-positive cells
are resistant to apoptosis because of the presence of EBV in cells. The
data presented here are typical results from three independent
experiments. (B) The average relative survival rates of reinfected
clones are significantly higher than those of NeoR- and
EBNA-1-transfected clones (**, < 0.005; ***, < 0.05),
suggesting that EBV-infected cells are resistant to apoptosis because
of the presence of EBV in cells. The data presented here are typical
results from three independent experiments. The numbers of clones
tested are noted beneath the graph. Significance values between the
indicated groups were determined by unpaired Student's t
test.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
Western blot analysis of LMP1, BHRF1, and
bcl-2 protein. (A and B) LMP1 (A) and BHRF1 (B) (arrows) are
detected only after cells are treated with anti-IgG, which induces the
virus lytic cycle, indicating that these proteins are lytic gene
products rather than latent gene products. Minor bands appear to be
degraded proteins. (C) bcl-2 protein expression (arrow) of
EBV-positive and -negative cell clones derived from parental Akata
cells (four clones each). (D) bcl-2 protein expression
(arrow) of EBV-reinfected and neoR-transfected clones
derived from an EBV-negative Akata clone (three clones each).
bcl-2 protein is expressed at a higher level in EBV-infected
clones than in uninfected clones. Molecular masses of protein markers
are shown at the left of each panel.
|
|
We then examined expression of
bcl-2 protein, an oncogene
having an antiapoptotic function, in EBV-infected and uninfected
cells.
In Western blotting, EBV-positive clones from the parental
Akata cells
were shown to express a higher level of
bcl-2 protein
than
did EBV-negative clones (Fig.
5C). Furthermore, expression
of
bcl-2 protein was higher in reinfected clones than in
neoR-transfected
clones (Fig.
5D).
EBNA-1 alone cannot induce malignant phenotype and apoptosis
resistance in Akata cells.
To investigate whether EBNA-1 was
responsible for the three phenotypes observed in the EBV-infected Akata
cells, anchorage-independent growth in soft agar, tumorigenicity in
SCID mice, and apoptosis resistance, we isolated EBNA-1-expressing
clones by transfecting EBNA-1/oriP vector, which contains
neoR also, into EBV-negative Akata clones and selected
stable transformants in the selection medium. Because all the
G418-resistant cells should carry this mammalian plasmid vector, 100%
of the G418-resistant cells were positive for EBNA-1 as shown by
immunofluorescence (data not shown). We isolated more than 100 G418-resistant clones and selected several clones randomly. Those
EBNA-1-transfected clones expressed amounts of EBNA-1 protein almost
equivalent to those of reinfected clones, as shown in Fig.
6; however, they did not acquire the
capacity to grow in soft agar, tumorigenicity in SCID mice, and
resistance to apoptosis (Table 2) (Fig. 2, 4, and 6).
EBNA-1-transfected cells expressed as little bcl-2 protein
as did neoR-transfected cells as a matter of course (data
not shown). These data suggested that EBNA-1 alone was responsible for
neither the malignant phenotype nor the resistance to apoptosis of
Akata cells.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 6.
Detection of EBNA-1 protein in an EBV-reinfected Akata
clone and three EBNA-1-transfected Akata clones by Western blot
analysis. EBNA-1 (arrow) is expressed in the EBNA-1-transfected clones
in an amount nearly equal to that of the EBV-reinfected clone.
Molecular masses of protein markers are shown at the left.
|
|
 |
DISCUSSION |
In the present study, we compared two pairs of cell clones:
EBV-positive and -negative clones from parental Akata cells and neoR-transfected and EBV-reinfected clones from EBV-negative
Akata cell clones. This system made it possible to confirm whether any phenotypic difference between EBV-infected and uninfected Akata cell
clones was due to EBV. In other words, this system provided an
excellent and powerful tool to investigate the pathogenic role of EBV
in BL. The unique characteristics of Akata cells, that is, spontaneous
loss of EBV DNA from cells during long-term culture and restoration of
type I latency by reinfection with EBV, made it possible to establish
this system. Other EBV-negative B-cell lines such as BJAB are not ideal
hosts for infection study since EBV infection leads to type III latency
(unpublished observations), which does not represent in vivo BL
latency.
Using this system, we demonstrated that reinfection of EBV-negative
Akata clones with EBV restores the ability to grow on soft agar,
tumorigenicity in SCID mice, and resistance to apoptosis. Accordingly,
it was concluded that these three phenotypes are due to EBV infection.
Under the ordinary culture conditions in the medium with 10% FBS,
EBV-reinfected Akata cells lose EBV plasmids very easily, because cells
possibly do not require EBV for growth under such conditions
(unpublished observation). Therefore, it is noteworthy that almost all
tumor cells in SCID mice retained EBV as shown by EBNA-1 expression,
suggesting that the presence of EBV is critical for tumor formation.
This is the first report providing evidence that EBV-infected BL cells
with type I latency are resistant to apoptosis. This may be due to
increased expression of bcl-2 protein. The bcl-2 family of proteins appears to be located downstream of any signaling cascades of apoptosis determining the life-death balance of a cell. In
Akata cells, a viral gene or genes other than LMP1 must upregulate
expression of bcl-2. Our findings imply the presence of an
unknown pathway by which EBV modulates the life of host cells.
Required for the maintenance of EBV DNA in a cell, EBNA-1 is expressed
in all EBV-infected cells with any type of latency. Whether EBNA-1
plays an oncogenic role in the human cancer cell was an open question.
EBNA-1 has been shown to be associated with the development of lymphoma
in a transgenic mouse study (24). EBNA-1 has also been
reported to increase tumorigenicity and metastatic capability of
nasopharyngeal carcinoma cells in a mouse model (15). Those
reports suggest that EBNA-1 may have an oncogenic function. If so, it
is likely that EBNA-1 is responsible for the malignant phenotype and
the resistance to apoptosis of the human BL cell line Akata. However,
our results indicated that EBNA-1 alone was not responsible for those
two phenotypes.
Then which virus gene is responsible for those two phenotypes of Akata
cells? Three other virus gene products
EBERs, BARF0, and LMP2A
are
expressed in the cells. It is not yet known whether they have any
functions in BL genesis. It has been reported that they are not
necessary for immortalization of primary B cells by EBV infection
(9, 13, 20). They or a novel virus gene(s) might be required
for those two phenotypes of Akata cells. We are currently attempting to
identify the responsible virus gene(s).
 |
ACKNOWLEDGMENTS |
We thank all the members of our laboratory, especially K. Adachi
for her excellent technical assistance. We thank R. F. Margolskee for pEBO.
This work was supported in part by grants-in-aid from the Ministry of
Education, Science, Sports, and Culture, Japan, and from the Vehicle
Racing Commemorative Foundation and the Suhara Foundation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Virology, Cancer Institute, Hokkaido University School of Medicine, N15 W7, Kita-ku, Sapporo 060-8638, Japan. Phone: 81-11-706-5071. Fax: 81-11-717-1128. E-mail: kentaka{at}med.hokudai.ac.jp
 |
REFERENCES |
| 1.
|
Brooks, L.,
Q. Y. Yao,
A. B. Rickinson, and L. S. Young.
1992.
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
J. Virol.
66:2689-2697[Abstract/Free Full Text].
|
| 2.
|
Burkitt, D.
1958.
A sarcoma involving the jaws in African children.
Br. J. Surg.
46:218-219[Medline].
|
| 3.
|
Deacon, E. M.,
G. Pallesen,
G. Niedobitek,
J. Crocker,
L. Brooks,
A. B. Rickinson, and L. S. Young.
1993.
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
J. Exp. Med.
177:339-349[Abstract/Free Full Text].
|
| 4.
|
Epstein, M. A.,
B. G. Achong, and Y. M. Barr.
1964.
Virus particles in cultured lymphoblasts from Burkitt's lymphoma.
Lancet
i:702-703.
|
| 5.
|
Henle, G.,
W. Henle, and V. Diehl.
1968.
Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis.
Proc. Natl. Acad. Sci. USA
59:94-101[Free Full Text].
|
| 6.
|
Henle, W., and G. Henle.
1979.
The virus as the etiologic agent of infectious mononucleosis, p. 297-320.
In
M. A. Epstein, and B. G. Achong (ed.), The Epstein-Barr virus. Springer-Verlag, Berlin, Germany.
|
| 7.
|
Imai, S.,
S. Koizumi,
M. Sugiura,
M. Tokunaga,
Y. Uemura,
N. Yamamoto,
S. Tanaka,
E. Sato, and T. Osato.
1994.
Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein.
Proc. Natl. Acad. Sci. USA
91:9131-9135[Abstract/Free Full Text].
|
| 8.
|
Imai, S.,
J. Nishikawa, and K. Takada.
1998.
Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells.
J. Virol.
72:4371-4378[Abstract/Free Full Text].
|
| 9.
|
Longnecker, R.,
C. L. Miller,
B. Tomkinson,
X. Q. Miao, and E. Kieff.
1993.
Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B.
J. Virol.
67:5068-5074[Abstract/Free Full Text].
|
| 10.
|
Margolskee, R. F.,
P. Kavathas, and P. Berg.
1988.
Epstein-Barr virus shuttle vector for stable episomal replication of cDNA expression libraries in human cells.
Mol. Cell. Biol.
8:2837-2847[Abstract/Free Full Text].
|
| 11.
|
Nonoyama, M.,
C. H. Huang,
J. S. Pagano,
G. Kline, and S. Singh.
1973.
DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma.
Proc. Natl. Acad. Sci. USA
70:3265-3268[Abstract/Free Full Text].
|
| 12.
|
Rickinson, A. B., and E. Kieff.
1996.
Epstein-Barr virus, p. 2397-2446.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
|
| 13.
|
Robertson, E. S.,
B. Tomkinson, and E. Kieff.
1994.
An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro.
J. Virol.
68:1449-1458[Abstract/Free Full Text].
|
| 14.
|
Rowe, M.,
D. T. Rowe,
C. D. Gregory,
L. S. Young,
P. J. Farrell,
H. Rupani, and A. B. Rickinson.
1987.
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.
EMBO J.
6:2743-2751[Medline].
|
| 15.
|
Sheu, L. F.,
A. Chen,
C. L. Meng,
K. C. Ho,
W. H. Lee,
F. J. Leu, and C. F. Chao.
1996.
Enhanced malignant progression of nasopharyngeal carcinoma cells mediated by the expression of Epstein-Barr nuclear antigen 1 in vivo.
J. Pathol.
180:243-248[Medline].
|
| 16.
|
Shibata, D., and L. M. Weiss.
1992.
Epstein-Barr virus-associated gastric adenocarcinoma.
Am. J. Pathol.
140:769-774[Abstract].
|
| 17.
|
Shimizu, N.,
A. Tanabe-Tochikura,
Y. Kuroiwa, and K. Takada.
1994.
Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV.
J. Virol.
68:6069-6073[Abstract/Free Full Text].
|
| 18.
|
Shimizu, N.,
H. Yoshiyama, and K. Takada.
1996.
Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells.
J. Virol.
70:7260-7263[Abstract/Free Full Text].
|
| 19.
|
Sugiura, M.,
S. Imai,
M. Tokunaga,
S. Koizumi,
M. Uchizawa,
K. Okamoto, and T. Osato.
1996.
Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumor cells.
Br. J. Cancer
74:625-631[Medline].
|
| 20.
|
Swaminathan, S.,
B. Tomkinson, and E. Kieff.
1991.
Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro.
Proc. Natl. Acad. Sci. USA
88:1546-1550[Abstract/Free Full Text].
|
| 21.
|
Takada, K.,
K. Horinouchi,
Y. Ono,
T. Aya,
T. Osato,
M. Takahashi, and S. Hayasaka.
1991.
An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA.
Virus Genes
5:147-156[Medline].
|
| 22.
|
Takada, K., and Y. Ono.
1989.
Synchronous and sequential activation of latently infected Epstein-Barr virus genomes.
J. Virol.
63:445-449[Abstract/Free Full Text].
|
| 23.
|
Tierney, R. J.,
N. Steven,
L. S. Young, and A. B. Rickinson.
1994.
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
J. Virol.
68:7374-7385[Abstract/Free Full Text].
|
| 24.
|
Wilson, J. B.,
J. L. Bell, and A. J. Levine.
1996.
Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice.
EMBO J.
15:3117-3126[Medline].
|
| 25.
|
Yoshiyama, H.,
N. Shimizu, and K. Takada.
1995.
Persistent Epstein-Barr virus infection in a human T-cell line: unique program of latent virus expression.
EMBO J.
14:3706-3711[Medline].
|
| 26.
|
zur Hausen, H.,
H. Schulte-Holthausen,
G. Kline,
W. Henle,
G. Henle,
P. Clifford, and L. Santesson.
1970.
EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx.
Nature
228:1056-1058[Medline].
|
Journal of Virology, November 1998, p. 9150-9156, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
O'Neil, J. D., Owen, T. J., Wood, V. H. J., Date, K. L., Valentine, R., Chukwuma, M. B., Arrand, J. R., Dawson, C. W., Young, L. S.
(2008). Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J. Gen. Virol.
89: 2833-2842
[Abstract]
[Full Text]
-
Brady, G, MacArthur, G J, Farrell, P J
(2008). Epstein-Barr virus and Burkitt lymphoma. Postgrad. Med. J.
84: 372-377
[Abstract]
[Full Text]
-
Kang, M.-S., Soni, V., Bronson, R., Kieff, E.
(2008). Epstein-Barr Virus Nuclear Antigen 1 Does Not Cause Lymphoma in C57BL/6J Mice. J. Virol.
82: 4180-4183
[Abstract]
[Full Text]
-
Brady, G, MacArthur, G J, Farrell, P J
(2007). Epstein Barr virus and Burkitt lymphoma. J. Clin. Pathol.
60: 1397-1402
[Abstract]
[Full Text]
-
Ho, C.-H., Hsu, C.-F., Fong, P.-F., Tai, S.-K., Hsieh, S.-L., Chen, C.-J.
(2007). Epstein-Barr Virus Transcription Activator Rta Upregulates Decoy Receptor 3 Expression by Binding to Its Promoter. J. Virol.
81: 4837-4847
[Abstract]
[Full Text]
-
Kelly, G. L., Rickinson, A. B.
(2007). Burkitt Lymphoma: Revisiting the Pathogenesis of a Virus-Associated Malignancy. ASH Education Book
2007: 277-284
[Abstract]
[Full Text]
-
Kelly, G. L., Milner, A. E., Baldwin, G. S., Bell, A. I., Rickinson, A. B.
(2006). Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA
103: 14935-14940
[Abstract]
[Full Text]
-
Ruf, I. K., Lackey, K. A., Warudkar, S., Sample, J. T.
(2005). Protection from Interferon-Induced Apoptosis by Epstein-Barr Virus Small RNAs Is Not Mediated by Inhibition of PKR. J. Virol.
79: 14562-14569
[Abstract]
[Full Text]
-
Baumforth, K. R. N., Flavell, J. R., Reynolds, G. M., Davies, G., Pettit, T. R., Wei, W., Morgan, S., Stankovic, T., Kishi, Y., Arai, H., Nowakova, M., Pratt, G., Aoki, J., Wakelam, M. J. O., Young, L. S., Murray, P. G.
(2005). Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood
106: 2138-2146
[Abstract]
[Full Text]
-
Kelly, G. L., Milner, A. E., Tierney, R. J., Croom-Carter, D. S. G., Altmann, M., Hammerschmidt, W., Bell, A. I., Rickinson, A. B.
(2005). Epstein-Barr Virus Nuclear Antigen 2 (EBNA2) Gene Deletion Is Consistently Linked with EBNA3A, -3B, and -3C Expression in Burkitt's Lymphoma Cells and with Increased Resistance to Apoptosis. J. Virol.
79: 10709-10717
[Abstract]
[Full Text]
-
Fukuda, M., Longnecker, R.
(2005). Epstein-Barr Virus (EBV) Latent Membrane Protein 2A Regulates B-Cell Receptor-Induced Apoptosis and EBV Reactivation through Tyrosine Phosphorylation. J. Virol.
79: 8655-8660
[Abstract]
[Full Text]
-
Kang, M.-S., Lu, H., Yasui, T., Sharpe, A., Warren, H., Cahir-McFarland, E., Bronson, R., Hung, S. C., Kieff, E.
(2005). Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc. Natl. Acad. Sci. USA
102: 820-825
[Abstract]
[Full Text]
-
Thompson, M. P., Kurzrock, R.
(2004). Epstein-Barr Virus and Cancer. Clin. Cancer Res.
10: 803-821
[Abstract]
[Full Text]
-
Trivedi, P., Takazawa, K., Zompetta, C., Cuomo, L., Anastasiadou, E., Carbone, A., Uccini, S., Belardelli, F., Takada, K., Frati, L., Faggioni, A.
(2004). Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. Blood
103: 313-316
[Abstract]
[Full Text]
-
Kennedy, G., Komano, J., Sugden, B.
(2003). Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc. Natl. Acad. Sci. USA
100: 14269-14274
[Abstract]
[Full Text]
-
Kiss, C., Nishikawa, J., Takada, K., Trivedi, P., Klein, G., Szekely, L.
(2003). T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus- carrying Burkitt lymphoma lines. Proc. Natl. Acad. Sci. USA
100: 4813-4818
[Abstract]
[Full Text]
-
Sheng, W., Decaussin, G., Ligout, A., Takada, K., Ooka, T.
(2003). Malignant Transformation of Epstein-Barr Virus-Negative Akata Cells by Introduction of the BARF1 Gene Carried by Epstein-Barr Virus. J. Virol.
77: 3859-3865
[Abstract]
[Full Text]
-
Maruo, S., Nanbo, A., Takada, K.
(2001). Replacement of the Epstein-Barr Virus Plasmid with the EBER Plasmid in Burkitt's Lymphoma Cells. J. Virol.
75: 9977-9982
[Abstract]
[Full Text]
-
Israel, B. F., Pickles, R. J., Segal, D. M., Gerard, R. D., Kenney, S. C.
(2001). Enhancement of Adenovirus Vector Entry into CD70-Positive B-Cell Lines by Using a Bispecific CD70-Adenovirus Fiber Antibody. J. Virol.
75: 5215-5221
[Abstract]
[Full Text]
-
Komano, J., Takada, K.
(2001). Role of bcl-2 in Epstein-Barr Virus-Induced Malignant Conversion of Burkitt's Lymphoma Cell Line Akata. J. Virol.
75: 1561-1564
[Abstract]
[Full Text]
-
Swart, R., Ruf, I. K., Sample, J., Longnecker, R.
(2000). Latent Membrane Protein 2A-Mediated Effects on the Phosphatidylinositol 3-Kinase/Akt Pathway. J. Virol.
74: 10838-10845
[Abstract]
[Full Text]
-
Ruf, I. K., Rhyne, P. W., Yang, C., Cleveland, J. L., Sample, J. T.
(2000). Epstein-Barr Virus Small RNAs Potentiate Tumorigenicity of Burkitt Lymphoma Cells Independently of an Effect on Apoptosis. J. Virol.
74: 10223-10228
[Abstract]
[Full Text]
-
Takada, K
(2000). Epstein-Barr virus and gastric carcinoma. Mol. Pathol.
53: 255-261
[Abstract]
[Full Text]
-
Komano, J., Maruo, S., Kurozumi, K., Oda, T., Takada, K.
(1999). Oncogenic Role of Epstein-Barr Virus-Encoded RNAs in Burkitt's Lymphoma Cell Line Akata. J. Virol.
73: 9827-9831
[Abstract]
[Full Text]
-
Marshall, W. L., Yim, C., Gustafson, E., Graf, T., Sage, D. R., Hanify, K., Williams, L., Fingeroth, J., Finberg, R. W.
(1999). Epstein-Barr Virus Encodes a Novel Homolog of the bcl-2 Oncogene That Inhibits Apoptosis and Associates with Bax and Bak. J. Virol.
73: 5181-5185
[Abstract]
[Full Text]
-
Nishikawa, J., Imai, S., Oda, T., Kojima, T., Okita, K., Takada, K.
(1999). Epstein-Barr Virus Promotes Epithelial Cell Growth in the Absence of EBNA2 and LMP1 Expression. J. Virol.
73: 1286-1292
[Abstract]
[Full Text]